Roquefort Therapeutics plc (ROQ.L) Comparison with companies in other sectors?

Roquefort Therapeutics plc has a share price of 157.44M. You can analyze Roquefort Therapeutics plc (ROQ.L) competitors across different market sectors through stock heatmaps.

What are ROQ.L's NET and operating margins?

Roquefort Therapeutics plc (ROQ.L) operating margin is around 95.95, and net profit margin is approximately -570.57 as of the latest reports.

In what way does ROQ.L's earnings per share (EPS) trend reflect its financial momentum?

Roquefort Therapeutics plc (ROQ.L) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Roquefort Therapeutics plc is -1.65, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Roquefort Therapeutics plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Roquefort Therapeutics plc like P/E which is -1.38, P/B which is 0.43, and PEG which is -9.75. Compare them with sector averages to evaluate if the stock is priced fairly.

Roquefort Therapeutics plc

ROQ.L•LSE

Healthcare

Biotechnology

£1.50

£-0.20(-11.76%)

Roquefort Therapeutics plc (ROQ.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.01

P/E Ratio

-1.65

ROE

-0.30%

Net Margin

-570.57%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.60M

Shares OutstandingTotal number of shares issued

$157.44M

Book Value/ShareNet worth per share

$0.04

Revenue/ShareAnnual revenue per share

$0.00

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

-57057.07%

Operating MarginOperating income as percentage of revenue

9594.52%

ROEReturn on shareholders' equity

-29.57%

ROAReturn on total assets

-25.38%

ROCEReturn on capital employed

4.97%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.01

Cash/ShareCash and equivalents per share

$0.005

FCF YieldFree cash flow as percentage of market cap

-52.72%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ROQ.LFinancial Ratios Analysis details for ROQ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ROQ.LSector Benchmarking details for ROQ.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Roquefort Therapeutics plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Roquefort Therapeutics plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Roquefort Therapeutics plc's unique business strengths and challenges.

Key Financial Metrics for Roquefort Therapeutics plc

For Roquefort Therapeutics plc, essential financial indicators include EPS -0.01, PE -1.65, and ROE -0.30. These key ratios reveal insights into Roquefort Therapeutics plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Roquefort Therapeutics plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Roquefort Therapeutics plc

Metrics like Net Margin -57057.07% and ROA -25.38% shed light on how well Roquefort Therapeutics plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Roquefort Therapeutics plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Roquefort Therapeutics plc

Using ratios such as P/B Ratio 0.43 and PEG Ratio -9.75, investors can assess whether Roquefort Therapeutics plc is appropriately valued based on its financials and growth potential. These figures, combined with Roquefort Therapeutics plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Roquefort Therapeutics plc

Financial health indicators, such as Debt/Equity Ratio 0.12 and Cash Flow $-0.01, provide a snapshot of Roquefort Therapeutics plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Roquefort Therapeutics plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Roquefort Therapeutics plc

Investing in Roquefort Therapeutics plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Roquefort Therapeutics plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;